Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system.
Kengo HariganeYuichi MochidaTakayuki ShimazakiNaomi KobayashiYutaka InabaPublished in: Cost effectiveness and resource allocation : C/E (2022)
Cost-effectiveness is clearly higher for MTX than biologics from the standpoint of mean total health care cost per adjusted NNT under the Japanese health insurance system.